On the control of the plasma contact activation system on human endothelium: Comparisons with heparin surface

Thrombosis Research

Volumn 93, Issue 1, 1999, Pages 27-34

  Sánchez, Javier ^a   Olsson, Per ^a  

^a K   (Sweden)

Author keywords

Antithrombin; Endothelium; Exogenous heparin; FXII; FXIIa; Heparin surface

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; ELLAGIC ACID; HEPARAN SULFATE; HEPARIN;

ADULT; AGED; ARTICLE; BINDING SITE; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; HUMAN TISSUE; MALE; PLASMA; PRIORITY JOURNAL; SAPHENOUS VEIN; VASCULAR ENDOTHELIUM;

EID: 0345435118     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00148-0     Document Type: Article

References (29)

1. Larm O., Larsson R., Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs. 11:1983;161-163.
2. Elgue G., Sanchez J., Egberg N., Olsson P., Riesenfeld J. Effect of surface-immobilized heparin on the activation of adsorbed factor XII. Artif Organs. 17:1993;721-726.
3. Sanchez J., Elgue G., Riesenfeld J., Olsson P. Control of contact activation on end-point immobilized heparin. The role of antithrombin and the specific antithrombin-binding sequence J Biomed Mater Res. 29:1995;655-661.
4. Sanchez J., Elgue G., Riesenfeld J., Olsson P. Studies of adsorption, activation and inhibition of Factor XII on immobilized heparin. Thromb Res. 89:1998;41-50.
5. Revak S.D., Cochrane C.G., Bouma B.N., Griffin J.H. Surface and fluid phase activities of the two forms of activated Hageman factor produced during contact activation in plasma. J Exp Med. 147:1978;719-729.
6. Koul B., Vesterqvist O., Egberg N., Steen S. Twenty-four-hour heparin-free veno-right ventricular ECMO. An experimental study Ann Thorac Surg. 53:1992;1046-1051.
7. Borowiec J., Thelin S., Bagge L., Nilsson L., Venge P., Hansson H.-E. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. J Thorac Cardiovasc Surg. 3:1992;642-647.
8. Mollnes T.E., Riesenfeld J., Garred P., Nordström E., Hogasen K., Fosse E., Gotze O., Harboe M. A new model for evaluation of biocompatibility. Combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin Artif Organs. 19:1995;909-917.
9. de Agostini A.I., Watkins S.C., Slayter H.S., Yousoufian H., Rosenberg R.D. Localization of anticoagulantly active heparan sulphate proteoglycans in vascular endothelium. antithrombin binding on cultured endothelial cells and perfused rata aorta J Cell Biol. 111:1990;1293-1304.
10. Joseph K., Ghebrehiwet B., Peerschke E.I., Reid K.B., Kaplan A.P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII. Identity with the receptor that binds to the globular "heads" of C1q (gC1q-R) Proc Natl Acad Sci USA. 93:1996;8552-8557.
11. Xu Y., Slayter H. Immunocytochemical localization of endogenous anti-thrombin III in the vasculature of rat tissues reveals locations of anticoagulantly active heparan sulfate proteoglycans. J Histochem Cytochem. 42:1994;1365-1376.
12. Sanchez J., Elgue G., Riesenfeld P., Olsson P. Inhibition of plasma contact activation system of immobilized heparin. Relation to surface density of functional antithrombin binding sites J Biomed Mater Res. 37:1997;37-42.
13. Tankersley D.L., Finlayson J.S. Kinetics of activation and autoactivation of human factor XII. Biochemistry. 23:1984;273-279.
14. Elgue G., Sanchez J., Fatah K., Olsson P., Blombäck B. The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure. Thromb Res. 75:1994;203-212.
15. Elgue G., Blombäck M., Olsson P., Riesenfeld J. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Thromb Haemost. 70:1993;289-293.
16. Stead N., Kaplan A.P., Rosenberg R.D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem. 251:1976;6481-6488.
17. Reddigari S.R., Shibayama Y., Brunnee T., Kaplan A.P. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem. 268:1993;11982-11987.
18. Marcum J.A., Atha D.H., Fritzel M.S., Nawroth P.P., Ster D.M., Rosenberg R.D. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulphate proteoglycan. J Biol Chem. 261:1986;7507-7517.
19. Kojima T., Shworak N., Rosenberg R.D. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem. 267:1992;4870-4877.
20. Kojima T., Leone C.W., Marchildon G.A., Marcum J.A., Rosenberg R.D. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem. 267:1992;4859-4869.
21. Sanchez J., Elgue G., Riesendfeld J., Olsson P. Antithrombin mediated inhibition of the plasma contact activation system on immobilized heparin. Thromb Haemost. Suppl:1997;211.
22. Hiebert L.M., Jaques L.B. The observation of heparin on endothelium after injection. Thromb Res. 8:1976;195-204.
23. Glimelius B., Busch C., Höök M. Binding of heparin on the surface of cultured human endothelial cells. Thromb Res. 12:1978;773-782.
24. Silverberg M., Diehl S.V. The autoactivation of Factor XII (Hageman factor) induced by low-MW heparin and dextran sulphate. Biochem J. 248:1987;715-720.
25. Frebelius S., Nydahl S., Swedenborg J. Coagulant and noncoagulant thrombin enzymatic activity on the endothelium. Blood Coagul Fibrinolysis. 1:1990;285-292.
26. de Agostini A.I., Lijnen H.R., Pixley R.A., Colman R.W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J Clin Invest. 73:1984;1452-1489.
27. Dryjski M., Larsson R., Olsson P., Swedenborg J. Effect of glycosaminoglycans and antithrombin III on uptake and inhibition of thrombin by the vascular wall. Thromb Res. 32:1983;355-363.
28. Stern D., Nawroth P., Marcum J., Handley D., Kisiel W., Rosenberg R.D., Stern K. Interaction of antithrombin III with bovine aortic segments. Role of heparin and enhanced anticoagulant activity. J Clin Invest. 75:1985;272-279.
29. Henderson L., Figueroa C., Muller-Esterl W., Bhoola K. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood. 84:1994;474-482.